RE: Every day gaining confidence.27 Jan 2021 17:47
And
'Manufacturing scale up – agreement with Akron Biotechnology
Synairgen has signed an agreement with Akron Biotechnology, a leading provider of cGMP-compliant
solutions to support the development of advanced therapies, to supply SNG001 drug substance in order
to meet expected clinical and commercial demand for the drug. Akron have the capacity to scale up
production of SNG001, with the aim of producing approximately 100,000 treatment courses per month in
2021. Lead times mean that the investment for this scale-up is required now. The SGO018 Phase III trial
will commence using Rentschler-derived drug substance, with the Akron-derived drug substance intended
to be introduced during the trial in preparation for commercial supply.'